Inflation Reduction Act Favors Biologics Over Small Molecules: In The Long Term, This Could Partly Undermine Bill’s Effort To Contain Costs Because the Inflation Reduction Act gives small molecule drugs a shorter, 9-year post-approval window before their “fair prices” are implemented, executives in the pharmaceutical industry have argued that the IRA will “harm innovation,” in particular, with respect to small molecules.